Goran Walldius

Summary

Affiliation: AstraZeneca R and D

Publications

  1. ncbi request reprint The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence
    G Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    J Intern Med 259:493-519. 2006
  2. ncbi request reprint Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I--new risk factors and targets for therapy
    Goran Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden AstraZeneca, Sodertalje, Sweden
    Nutr Metab Cardiovasc Dis 17:565-71. 2007
  3. ncbi request reprint Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke
    Goran Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    Curr Opin Cardiol 22:359-67. 2007
  4. ncbi request reprint [The apoB/apoA-I ratio is better myocardial infarction marker than lipids]
    Goran Walldius
    Karolinska Institutet, Stockholm
    Lakartidningen 103:751-2. 2006
  5. ncbi request reprint Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study
    G Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    J Intern Med 259:259-66. 2006
  6. ncbi request reprint [Apolipoproteins are new and better risk indicators of myocardial infarction]
    Goran Walldius
    Konung Gustaf V forskningsinstitut, Karolinska Institutet, Stockholm
    Lakartidningen 101:1188-94. 2004
  7. ncbi request reprint Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy
    G Walldius
    King Gustaf V Research Institute and Karolinska Institute, Stockholm, Sweden
    J Intern Med 255:188-205. 2004
  8. ncbi request reprint High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study
    G Walldius
    Astra Zeneca, Mölndal and King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    Lancet 358:2026-33. 2001
  9. ncbi request reprint [Apolipoproteins are better risk markers than conventional lipids]
    Goran Walldius
    Konung Gustaf V s forskningsinstitut, Solna, AstraZeneca AB, Sodertalje
    Lakartidningen 104:2612-3. 2007
  10. ncbi request reprint The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk
    Goran Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    Clin Chem Lab Med 42:1355-63. 2004

Collaborators

Detail Information

Publications18

  1. ncbi request reprint The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence
    G Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    J Intern Med 259:493-519. 2006
    ..Guidelines should be developed in order to recognize the important clinical risk information embedded in the apoB/apoA-I ratio...
  2. ncbi request reprint Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I--new risk factors and targets for therapy
    Goran Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden AstraZeneca, Sodertalje, Sweden
    Nutr Metab Cardiovasc Dis 17:565-71. 2007
    ....
  3. ncbi request reprint Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke
    Goran Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    Curr Opin Cardiol 22:359-67. 2007
    ..To compare the potential of high-density lipoprotein (HDL) cholesterol and apolipoprotein (apo) A-I, the major protein in HDL particles, in predicting cardiovascular risk. Pros and cons for using these risk markers are discussed...
  4. ncbi request reprint [The apoB/apoA-I ratio is better myocardial infarction marker than lipids]
    Goran Walldius
    Karolinska Institutet, Stockholm
    Lakartidningen 103:751-2. 2006
  5. ncbi request reprint Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study
    G Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    J Intern Med 259:259-66. 2006
    ....
  6. ncbi request reprint [Apolipoproteins are new and better risk indicators of myocardial infarction]
    Goran Walldius
    Konung Gustaf V forskningsinstitut, Karolinska Institutet, Stockholm
    Lakartidningen 101:1188-94. 2004
    ..Methodological advantages speak in favour of measuring apoB and apoA-I in clinical practice...
  7. ncbi request reprint Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy
    G Walldius
    King Gustaf V Research Institute and Karolinska Institute, Stockholm, Sweden
    J Intern Med 255:188-205. 2004
    ..Measurement of these apolipoproteins could improve cardiovascular risk prediction...
  8. ncbi request reprint High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study
    G Walldius
    Astra Zeneca, Mölndal and King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    Lancet 358:2026-33. 2001
    ..We also aimed to establish whether apoB and apoA-I add further information about risk of fatal myocardial infarction to that obtained with total cholesterol, triglycerides, and LDL-cholesterol...
  9. ncbi request reprint [Apolipoproteins are better risk markers than conventional lipids]
    Goran Walldius
    Konung Gustaf V s forskningsinstitut, Solna, AstraZeneca AB, Sodertalje
    Lakartidningen 104:2612-3. 2007
  10. ncbi request reprint The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk
    Goran Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    Clin Chem Lab Med 42:1355-63. 2004
    ..Moreover, we examined whether any lipids, lipoproteins or cholesterol ratios add significant predictive information beyond that provided by the apoB/apoA-I ratio...
  11. doi request reprint Renal dysfunction increases the risk of ischemic and hemorrhagic stroke in the general population
    Martin J Holzmann
    Department of Emergency Medicine, Karolinska University Hospital, Stockholm, Sweden
    Ann Med 44:607-15. 2012
    ..We aimed to assess the impact of CKD on the risk of fatal or non-fatal ischemic and hemorrhagic stroke in both men and women...
  12. ncbi request reprint Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction?
    Ingmar Jungner
    Department of Medicine, Clinical Epidemiology Unit, Karolinska Institute, Stockholm, Sweden
    Am J Cardiol 97:943-6. 2006
    ..The strongest single lipoprotein-related risk factor was the apo-B/apo-A-I ratio. In conclusion, these results provide further confirmation of the importance of determining apo-B and apo-A-I in routine clinical practice...
  13. pmc Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population
    Justo Sierra-Johnson
    Atherosclerosis Research Unit, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital Solna, Building L8 03, S 17176 Stockholm, Sweden
    Eur Heart J 30:710-7. 2009
    ....
  14. doi request reprint Country of birth-specific and gender differences in prevalence of diabetes in Sweden
    Axel C Carlsson
    Centre for Family Medicine, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden
    Diabetes Res Clin Pract 100:404-8. 2013
    ..The aim was to investigate country or region of birth-specific prevalence and gender differences of diabetes in residents in Sweden, using Swedish-born men and women as referent...
  15. doi request reprint Dyslipidemia is a strong predictor of myocardial infarction in subjects with chronic kidney disease
    Martin J Holzmann
    Department of Emergency Medicine, Karolinska University Hospital, Stockholm, Sweden
    Ann Med 44:262-70. 2012
    ..To evaluate dyslipidemia as predictor of myocardial infarction (MI) in subjects with or without chronic kidney disease (CKD)...
  16. ncbi request reprint Apolipoprotein B and A-I values in 147576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Materials
    I Jungner
    CALAB Research and CALAB Medical Laboratories, S t Göran Hospital, Stockholm, Sweden
    Clin Chem 44:1641-9. 1998
    ....
  17. doi request reprint Renal function assessed by two different formulas and incidence of myocardial infarction and death in middle-aged men and women
    M J Holzmann
    Department of Emergency Medicine, Karolinska University Hospital, Stockholm, Sweden
    J Intern Med 267:357-69. 2010
    ..We evaluated glomerular filtration rates (GFR) estimated by the Modification of Diet in Renal Disease study (GFR-MDRD) equation and the Mayo formula (GFR-Mayo) as predictors of myocardial infarction and death...
  18. ncbi request reprint The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis
    J Regnstrom
    King Gustaf V Research Institute, Karolinska Hospital, Stockholm, Sweden
    Atherosclerosis 125:217-29. 1996
    ..The relevance of these observations for the proposed role of lipid oxidation in atherosclerosis is discussed...